Medigen Vaccine Biologics Corporation (MVC) and BlueWillow Biologics, Inc. announced a partnership to develop S-2P-NE-01, a nasal vaccine for SARS-CoV-2, the virus that causes COVID-19. While the majority of COVID-19 vaccines in development are delivered via intramuscular injection, research has demonstrated that nasal delivery – often the initial site of the infection - can prevent the virus from taking hold in the body. Preclinical research demonstrated that BlueWillow’s nasal vaccine adjuvant combined with Medigen’s S-2P spike protein resulted in an extremely high neutralizing antibody response, as well as a superior immunoglobulin A (IgA) response in both serum and lung secretions (BAL) samples in mice compared to intramuscular injection of S-2P adjuvanted with alum. Mucosal immune response is critical in reducing viral nasal colonization and preventing the spread of SARS-CoV-2.